Quantum BioPharma Ltd.
QNTM
$3.02
-$0.34-9.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.42% | 27.01% | 20.69% | 3.17% | -25.69% |
| Depreciation & Amortization | 11.27% | 5.86% | -4.03% | -66.58% | -80.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.17% | 67.28% | 76.31% | 42.47% | -16.10% |
| Operating Income | 5.17% | -67.28% | -76.31% | -42.47% | 16.10% |
| Income Before Tax | -80.73% | -158.40% | -240.09% | -108.06% | 18.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.73% | -158.40% | -240.09% | -108.06% | 18.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.65% | -76.99% | 26.89% | 33.20% | 117.08% |
| Net Income | -84.30% | -178.49% | -261.70% | -111.98% | 20.66% |
| EBIT | 5.17% | -67.28% | -76.31% | -42.47% | 16.10% |
| EBITDA | 5.68% | -70.08% | -80.52% | -57.83% | 6.47% |
| EPS Basic | 41.29% | 26.40% | -11.37% | 6.65% | 50.12% |
| Normalized Basic EPS | 36.36% | 15.88% | 3.67% | 9.53% | 50.28% |
| EPS Diluted | 41.29% | 26.40% | -11.37% | 6.68% | 50.61% |
| Normalized Diluted EPS | 36.36% | 15.88% | 3.67% | 9.53% | 50.28% |
| Average Basic Shares Outstanding | 216.30% | 306.51% | 241.31% | 148.36% | 72.12% |
| Average Diluted Shares Outstanding | 216.30% | 306.51% | 241.31% | 148.36% | 72.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |